BRIGHTCOVE
25.6.2020 15:12:07 CEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, today announced Brightcove Virtual Event Experiences , a solution that allows organizations to deliver high-quality virtual events featuring bold, interactive experiences. Responding to a crucial market need, Brightcove Virtual Event Experiences enables organizations to host events with market-leading video technology to engage with audiences securely and reliably around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005507/en/
The adoption of video communications in enterprise organizations is growing at a rapid pace. According to the recent Brightcove Global Video Index , in the first quarter of 2020, video views among enterprise companies increased by 91% year over year, with preliminary year-over-year data from April and May showing viewing increases of nearly 80% and 54%, respectively. Along with this adoption, many in-person events and meetings are moving to online video. With no timetable for the return of large-scale, in-person conferences and events, marketing and event professionals are looking for an in-person alternative, and they are turning to Brightcove for guidance. Recently, Brightcove technology has helped power critical B2B, B2C, and arts/entertainment events, helping organizations scale quickly, easily, and securely while reaching new audiences across the globe, including:
- ServiceNow Knowledge 2020
- DocuSign MomentumLive
- Talkdesk® Opentalk 2020 Virtual
- NAB Show Express with over 40,000 industry professionals accessing the event since its launch
- The Dropkick Murphys’ Streaming Outta Fenway concert joined by Bruce Springsteen with over 9 million live and on-demand views to date, raising over $700,000 for charity
- The Metropolitan Opera's At Home Gala, with more than 40 artists participating from around the world, was watched by more than 750,000 people
The need to engage with customers and prospects is as critical as ever, and organizations expect to deliver innovative and measurable experiences for their audiences in order to maintain communication and engagement. The Brightcove Virtual Events Experience solution empowers companies to take immediate action to ensure that their essential in-person events can continue virtually.
Features include:
- Branding and User Experience: Control the viewer’s experience and surrounding content by hosting on Brightcove.
- Increased Value for Sponsors: Demonstrate value to sponsors and exhibitors by offering integrated ads, complete with measurable and tangible analytics.
- Quality and Global Scale: Enable streaming video to global audiences in a secure environment.
- Security : Configure a variety of security options beyond password protection and geo-blocking, including SSO and integration with user management solutions.
- Expertise and support: Engage with Brightcove’s customer experience team and support organization to meet business objectives.
“Like most B2B companies, we had to quickly pivot from an in-person event to a virtual customer conference when COVID-19 hit. Our strategy was to embrace the remote reality but also to create an experience that felt like a performance and developed a sense of community,“ said Kathie Johnson, Chief Marketing Officer, Talkdesk. “To do this, we selected Brightcove as the platform and leveraged its integration partner Pigeonhole for the live polling and social interaction. One analyst who compared B2B customer conferences stated Opentalk 2020 virtual ‘struck the best balance of event duration, content, and engagement.’ The development process with Brightcove was seamless and the response to our program has been extremely positive.”
“The pandemic is video’s evolutionary moment, and as a result, video is now at the forefront of how we communicate with others, how we conduct business, and is enabling us to stay connected even when physically apart,” said Sara Larsen, Chief Marketing Officer, Brightcove. “Events are a place for information sharing, learning, business building, and networking. Now, more than ever, we need events to flourish and connect us in a virtual video experience. Brightcove Virtual Events Experiences allows organizations to deliver exceptional virtual events quickly and securely, without sacrificing the attendee experience. With this solution, we’re not only helping our customers adapt to the changing landscape but also allowing them to stay connected with their audiences with an engaging, innovative video-driven digital experience.”
For more information on Brightcove Virtual Event Experiences, visit: https://www.brightcove.com/en/solutions/virtual-event
About Brightcove Inc. (NASDAQ: BCOV)
We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.
Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005507/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
